EHA2021 Abstract S143 and EP631
THE HAGUE, The Netherlands,
June 11, 2021 /PRNewswire/ -- The
HARMONY Alliance will share new insights in Chronic Lymphocytic
Leukemia (CLL) at the virtual Annual Congress of the European
Hematology Association (EHA2021 from 9-17
June 2021). Dr Larry Mansouri
of Karolinska Institutet will give an
oral presentation and Dr Thomas
Chatzikonstantinou of the European Research Initiative on
CLL will give a poster presentation.
The clinical course of CLL is highly variable. Some patients
will never require treatment whereas others will develop a
treatment need over time. The disease is highly heterogeneous from
a genomic perspective as well. A limited number of recurrently
mutated genes are observed in more than 10% of patients, while
hundreds of other genes have been found to be mutated in only in a
fraction of patients. As a result, thousands of patients need to be
studied to obtain robust insights into the role of these mutations
in the course of the disease. The HARMONY Big Data Platform offers
excellent opportunities to do just that.
Oral presentation
At EHA2021, Dr Larry Mansouri of
Karolinska Institutet will give an oral
presentation about the results of a HARMONY research project that
aimed to assess the clinical impact of recurrent gene mutations in
CLL. Professor Richard Rosenquist
Brandell was the principal investigator in this study.
Centers across Europe were
asked to sequence the ten mostly commonly mutated genes in CLL in
their patients. There has been fantastic interest, therefore the
cohort now consists of more than 4,600 patients. The frequency of
the different mutations were studied. The team also studied the
association of the genes with time-to-first-treatment and overall
survival. This results may allow clinicians to give patients a more
reliable estimate of what they can expect in terms of the clinical
course of the disease. In addition, it may affect treatment
choices.
Poster presentation
Dr Thomas Chatzikonstantinou
(European Research Initiative on CLL, INAB, CERTH, Thessaloniki) will present a poster about
other malignancies in the history of CLL. The researchers
retrospectively evaluated data from 13,808 patients from 64
centers. They report strong associations between the development of
other hematological malignancies, especially MDS/AML, and certain
biological features, as well as treatment for CLL, with a highly
relevant risk for patients treated with CIT, particularly the FCR
regimen. In contrast, the development of solid tumors appeared
unaffected by treatment administration, prompting further
investigation in specific patient subgroups that will be presented
at the congress.
More information
- Link to the Oral session New biological and translational
insights in CLL to find out more: abstract S143: p408-4 (S143)
CLINICAL IMPACT OF RECURRENT GENE MUTATIONS IN CHRONIC LYMPHOCYTIC
LEUKEMIA: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY BY ERIC, THE
EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY Dr. Larry Mansouri.
- Link to the Poster session Chronic lymphocytic leukemia and
related disorders – Clinical: abstract EP631: OTHER MALIGNANCIES IN
THE HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE,
MULTICENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE
ON CLL, IN HARMONY - Dr. Thomas
Chatzikonstantinou.
- www.harmony-alliance.eu | #bigdataforbloodcancer
| @HARMONYnetEU
- Ellen de Waal, HARMONY
Manager Communication and Dissemination,
e.dewaal@ehaweb.org
The HARMONY Alliance (HARMONY and HARMONY
PLUS) is a public-private European Network of Excellence
for Big Data in Hematology, established in January 2017. Our mission is to unlock and spread
valuable knowledge on hematologic malignancies (blood cancers)
among a large number of stakeholders, with the
goal to harness and mine Big Data to speed up the development of
improved treatments for patients
and more effective treatment strategies.
- HARMONY and HARMONY PLUS are funded through the Innovative
Medicines Initiative (IMI), Europe's largest public-private initiative
aiming to speed up the development of better and safer medicines
for patients. Funding is received from the IMI 2 Joint Undertaking
and is listed under grant agreement for HARMONY No. 116026 and
grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking
receives support from the European Union's Horizon 2020 Research
and Innovation Programme and the European Federation of
Pharmaceutical Industries and Associations (EFPIA).
- HARMONY: 53 Partners and 43 Associated Members, including 7
European Patient Organizations from 18 countries. Budget: 40
million | Period: January 2017-
December 2021.
- HARMONY PLUS: 39 Partners from 10 countries. Budget 12 million
| Period: October 2020 – September 2023
Logo -
https://mma.prnewswire.com/media/1530884/Logo_Harmony_Alliance_RGB_Logo.jpg